Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 9/30/2015 | 6/30/2015 | 3/31/2015 | |
|---|---|---|---|---|
| Revenue | $1 | $2 | $1 | $1 |
| % Growth | -17.5% | 16.4% | 25.7% | – |
| Cost of Goods Sold | $1 | $0 | $1 | $1 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 60.2% | 68.2% | 60.2% | 48.4% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $1 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $2 |
| Operating Income | -$0 | -$0 | -$0 | -$1 |
| % Margin | -28.5% | -1.1% | -27.6% | -119.4% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$0 | -$1 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$0 | -$1 | -$2 |
| % Margin | -45.1% | -15.2% | -40.7% | -157.2% |
| EPS | -0.021 | -0.01 | -0.02 | -0.06 |
| % Growth | -114% | 50% | 66.7% | – |
| EPS Diluted | -0.021 | -0.01 | -0.02 | -0.06 |
| Weighted Avg Shares Out | 27 | 27 | 27 | 27 |
| Weighted Avg Shares Out Dil | 27 | 27 | 27 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | $0 | -$0 | -$1 |
| % Margin | -24.3% | 5.1% | -16.5% | -113% |